South Korea · Delayed Price · Currency is KRW INBIOGEN Statistics
Total Valuation
INBIOGEN has a market cap or net worth of KRW 53.12 billion. The enterprise value is 54.83 billion.
| Market Cap | 53.12B |
| Enterprise Value | 54.83B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
INBIOGEN has 9.98 million shares outstanding.
| Current Share Class | 9.98M |
| Shares Outstanding | 9.98M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | n/a |
| Float | 2.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.41 |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.37 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.11 |
| Interest Coverage | -27.73 |
Financial Efficiency
Return on equity (ROE) is -13.63% and return on invested capital (ROIC) is -2.73%.
| Return on Equity (ROE) | -13.63% |
| Return on Assets (ROA) | -1.57% |
| Return on Invested Capital (ROIC) | -2.73% |
| Return on Capital Employed (ROCE) | -2.76% |
| Weighted Average Cost of Capital (WACC) | 8.37% |
| Revenue Per Employee | 124.48M |
| Profits Per Employee | -505.54M |
| Employee Count | 41 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.80% in the last 52 weeks. The beta is 0.83, so INBIOGEN's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -54.80% |
| 50-Day Moving Average | 5,686.60 |
| 200-Day Moving Average | 9,017.55 |
| Relative Strength Index (RSI) | 47.13 |
| Average Volume (20 Days) | 4,722 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, INBIOGEN had revenue of KRW 5.10 billion and -20.73 billion in losses.
| Revenue | 5.10B |
| Gross Profit | -566.80M |
| Operating Income | -3.91B |
| Pretax Income | -20.73B |
| Net Income | -20.73B |
| EBITDA | -3.78B |
| EBIT | -3.91B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 2.34 billion in cash and 4.05 billion in debt, with a net cash position of -1.71 billion or -171.24 per share.
| Cash & Cash Equivalents | 2.34B |
| Total Debt | 4.05B |
| Net Cash | -1.71B |
| Net Cash Per Share | -171.24 |
| Equity (Book Value) | 141.50B |
| Book Value Per Share | n/a |
| Working Capital | 1.87B |
Cash Flow
In the last 12 months, operating cash flow was -3.64 billion and capital expenditures -4.10 million, giving a free cash flow of -3.64 billion.
| Operating Cash Flow | -3.64B |
| Capital Expenditures | -4.10M |
| Depreciation & Amortization | 126.29M |
| Net Borrowing | 3.27B |
| Free Cash Flow | -3.64B |
| FCF Per Share | -364.60 |
Margins
| Gross Margin | -11.11% |
| Operating Margin | -76.63% |
| Pretax Margin | -406.14% |
| Profit Margin | n/a |
| EBITDA Margin | -74.15% |
| EBIT Margin | -76.63% |
| FCF Margin | n/a |
Dividends & Yields
INBIOGEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -39.02% |
| FCF Yield | -6.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 21, 2023. It was a reverse split with a ratio of 0.05.
| Last Split Date | Sep 21, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
INBIOGEN has an Altman Z-Score of 11.54 and a Piotroski F-Score of 1.
| Altman Z-Score | 11.54 |
| Piotroski F-Score | 1 |